Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
HIV-1-infection
Interventions
DRUG

Standardised triple antiretroviral therapy

patients have to use Triple therapy antiretroviral drugs on their usual regimen containing an integrase inhibitor. There are many types of drugs within this group, so they are not specified.

DRUG

High doses Triple therapy antiretroviral drugs

dolutegravir 50 mg/12 h, maraviroc 300 mg/12 h and lamivudine 300 mg/12 h

Trial Locations (2)

28034

NOT_YET_RECRUITING

Hospital Universitario Ramón y Cajal, Madrid

Unknown

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

All Listed Sponsors
lead

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER